Innate Pharma SA
IPHA
Company Profile
Business description
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
Contact
117, Avenue de Luminy
Marseille13009
FRAT: +33 430303030
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
179
Stocks News & Analysis
stocks
Why we’ve downgraded this ASX software player
Morningstar lowers our fair value estimate for Megaport by 16% after mispricing leads to a downgrade in capital allocation rating.
stocks
The market hates this compelling ASX income play
Santos continues to trade at a valuation that implies no growth in the years ahead. Our analyst Mark Taylor thinks that is misguided.
stocks
Lessons from the top performing ASX share
Chasing performance can lead to poor results but investors can still learn from top performers.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,754.70 | 49.70 | 0.57% |
| CAC 40 | 7,255.42 | 18.53 | 0.26% |
| DAX 40 | 20,016.75 | 83.13 | 0.42% |
| Dow JONES (US) | 44,729.29 | 52.71 | -0.12% |
| FTSE 100 | 8,359.41 | 46.52 | 0.56% |
| HKSE | 19,746.32 | 196.03 | 1.00% |
| NASDAQ | 19,470.90 | 66.96 | 0.35% |
| Nikkei 225 | 39,248.86 | 735.84 | 1.91% |
| NZX 50 Index | 13,093.18 | 21.50 | -0.16% |
| S&P 500 | 6,050.78 | 3.63 | 0.06% |
| S&P/ASX 200 | 8,495.20 | 47.30 | 0.56% |
| SSE Composite Index | 3,378.81 | 14.82 | 0.44% |